Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial
The DOI matches its Crossref record.
Abstract
BACKGROUND: Uterine leiomyomas are widely prevalent and frequently cause menorrhagia. The major therapeutic option today is hysterectomy. Medical options are of highest interest. METHODS: A total of 30 women with uterine leiomyomas scheduled for surgical intervention were randomized to receive either 50 mg mifepristone or placebo every other day during 3 months prior to surgery. Uterine blood flow and leiomyoma volume were evaluated once a month until surgery. Endometrial biopsies were obtained prior to and at end of treatment. Relevant biochemistry, symptoms and bleeding were recorded. Primary outcome was reduction in uterine leiomyoma size. RESULTS: There was a significant percentual decrease (P = 0.021) in the total leiomyoma volume in the mifepristone-treated group, -28 (-48, -8) % (mean +/- 0, 95 confidence interval), compared with the control group values 6 (-13, 25) %. Mifepristone treatment significantly reduced the bleeding days (P = 0.001) and increased serum haemoglobin values (P = 0.046). Serum cortisol levels remained unchanged, while a mild increase in serum androgens was noted. Endometrial biopsies showed no premalignant changes or changes in mitotic indices. CONCLUSION: Mifepristone may offer an effective treatment option for women with uterine leiomyoma and the associated pronounced uterovaginal bleeding. Clinical Trials identifier: www.clinicaltrials.gov: NCT00579475.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Uterine fibroid management: From the present to the future
Donnez, J., & Dolmans, M.-M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw023 · Cited by 780
Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma
Ishikawa, H., Ishi, K., Serna, V. A., Kakazu, R., Bulun, S. E., & Kurita, T. (2010) · Endocrinology · doi:10.1210/en.2009-1225 · Cited by 362
Progesterone action in breast, uterine, and ovarian cancers
Diep, C. H., Daniel, A. R., Mauro, L. J., Knutson, T. P., & Lange, C. A. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0252 · Cited by 190
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
“A complete lack of vaginal bleeding was observed in 86% of women during the second month of mifepristone treatment and in close to 100% during the third month of mifepristone treatment, compared with no significant changes in the placebo group (125).”
BackgroundResultInfluentialWhitaker, L. H. R., Murray, A. A., Matthews, R., Shaw, G., Williams, A. R. W., Saunders, P. T. K., & Critchley, H. O. D. (2017) · Human Reproduction · doi:10.1093/humrep/dew359 · Cited by 77
“Administration of the SPRMs mifepristone and asoprisnil has been reported to reduce both fibroid volume and menstrual blood loss (Wilkens et al., 2008; Engman et al., 2009).”
Self-citation
Metadata
- Authors
- Engman, M., Granberg, S., Williams, A. R. W., Meng, C. X., Lalitkumar, P. G. L., & Gemzell-Danielsson, K.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-23
- Volume
- 24
- Issue
- 8
- Pages
- 1870-1879
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2155493571
- Cited by
- 127
- References
- 0
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.